Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen

J Clin Microbiol. 2012 Sep;50(9):3096-8. doi: 10.1128/JCM.00971-12. Epub 2012 Jul 3.

Abstract

Hepatitis B virus (HBV) surface antigen (HBsAg) decay was explored in HIV-1- and HBV-coinfected patients beginning antiretroviral (ARV) therapy containing tenofovir disoproxil fumarate (TDF). The mean HBsAg decay was 0.38 log(10) IU/ml/year (95% confidence interval [CI], 0.71 to 0.05) in 18 patients with sustained plasma HIV-1 RNA suppression and 0.15 log(10) IU/ml/year (0.21 to 0.09) in 12 patients experiencing HIV-1 virologic failure due to suboptimal adherence to ARV (P = 0.17). We estimated that six of these 18 patients will attain HBsAg values below 10 IU/ml after 10 years of treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Coinfection / drug therapy*
  • Coinfection / virology*
  • HIV Infections / drug therapy*
  • HIV-1 / isolation & purification
  • Hepatitis B Surface Antigens / blood*
  • Hepatitis B, Chronic / virology*
  • Humans
  • Middle Aged
  • Organophosphonates / administration & dosage*
  • Tenofovir
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents
  • Hepatitis B Surface Antigens
  • Organophosphonates
  • Tenofovir
  • Adenine